Literature DB >> 28029293

Pharmacokinetics of terbinafine in little brown myotis (Myotis lucifugus) infected with Pseudogymnoascus destructans.

Michael H Court, Alison H Robbins, Anne M Whitford, Erika V Beck, Flo S Tseng, DeeAnn M Reeder.   

Abstract

OBJECTIVE To determine the pharmacokinetics of terbinafine in little brown myotis (Myotis lucifugus) infected with Pseudogymnoascus destructans. ANIMALS 123 bats from a P destructans-infected hibernation site in Virginia. PROCEDURES 3 bats were euthanized and necropsied to confirm the presence of P destructans within the population. The remaining 120 bats were systematically assigned to 6 groups (20 bats/group). Bats in each of 3 groups received 6, 20, or 60 mg of terbinafine/kg, SC, once daily for 10 days. Bats in another group received 200 mg of terbinafine/kg, SC, once daily for 5 days. Bats in 1 group received the terbinafine vehicle solution (0.1 mL/kg, SC, once daily for 10 days). Bats in the remaining group did not receive any treatment. Following the treatment period (days 1 through 10), bats were housed in a hibernation chamber and monitored daily until euthanasia on day 42, 75, or 109. Tissue specimens were collected from all bats as soon as possible after death or euthanasia to determine terbinafine concentration. Within each group and tissue type, terbinafine concentration data were pooled, and pharmacokinetic parameters were calculated by noncompartmental methods. RESULTS Adverse neurologic effects and a high mortality rate before day 10 were observed in bats that received the highest terbinafine dose (200 mg/kg) but not those that received lower doses. Presumed therapeutic terbinafine concentrations (≥ 2 μg/g) were maintained in skin and wing for at least 30 and 6 days in bats that received the 60 and 20 mg/kg doses, respectively, but were not achieved in most bats that received the 6 mg/kg dose. Tissue terminal half-life ranged from 14 to 22 days. Terbinafine concentration in hair was positively correlated with that in skin and wing. CONCLUSIONS AND CLINICAL RELEVANCE Results indicated terbinafine doses > 6 but < 200 mg/kg should be further evaluated for the treatment of P destructans-infected bats. Collection of serial hair specimens may represent a noninvasive method for monitoring terbinafine concentration in treated bats.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28029293     DOI: 10.2460/ajvr.78.1.90

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  4 in total

Review 1.  Ecology and impacts of white-nose syndrome on bats.

Authors:  Joseph R Hoyt; A Marm Kilpatrick; Kate E Langwig
Journal:  Nat Rev Microbiol       Date:  2021-01-18       Impact factor: 60.633

Review 2.  Strategies to Better Target Fungal Squalene Monooxygenase.

Authors:  Alia A Sagatova
Journal:  J Fungi (Basel)       Date:  2021-01-13

3.  White-nose syndrome pathology grading in Nearctic and Palearctic bats.

Authors:  Jiri Pikula; Sybill K Amelon; Hana Bandouchova; Tomáš Bartonička; Hana Berkova; Jiri Brichta; Sarah Hooper; Tomasz Kokurewicz; Miroslav Kolarik; Bernd Köllner; Veronika Kovacova; Petr Linhart; Vladimir Piacek; Gregory G Turner; Jan Zukal; Natália Martínková
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

4.  Experimental inoculation trial to determine the effects of temperature and humidity on White-nose Syndrome in hibernating bats.

Authors:  Winifred F Frick; Emily Johnson; Tina L Cheng; Julia S Lankton; Robin Warne; Jason Dallas; Katy L Parise; Jeffrey T Foster; Justin G Boyles; Liam P McGuire
Journal:  Sci Rep       Date:  2022-01-19       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.